Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2023

Assaad MA, Gundem G, Liechty B, Sboner A, Medina J, Papaemmanuil E, et al. The importance of escalating molecular diagnostics in patients with low-grade pediatric brain cancer. Cold Spring Harb Mol Case Stud. 2023;9(4).

Ma C, Zhou Y, Fanelli GN, Stopsack KH, Fiorentino M, Zadra G, et al. The Prostate Stromal Transcriptome in Aggressive and Lethal Prostate Cancer. Mol Cancer Res. 2023;21(3):253-260.

Fischer GM, Lindeman NI, Ligon AH, Russell-Goldman E. Proliferating Pilar Tumors Are Characterized by Recurrent 15q, 6q, and 6p22.2 Alterations. Am J Dermatopathol. 2023;45(4):217-226.

Spisak S, Tisza V, Nuzzo PV, Seo J-, Pataki B, Ribli D, et al. A biallelic multiple nucleotide length polymorphism explains functional causality at 5p15.33 prostate cancer risk locus. Nat Commun. 2023;14(1):5118.

Zhang K, Potter RF, Marino J, Muenks CE, Lammers MG, Bard JD, et al. Comparative genomics reveals the correlations of stress response genes and bacteriophages in developing antibiotic resistance of Staphylococcus saprophyticus. mSystems. 2023;8(6):e0069723.

Folarin OS, Siddiqui MT. Are we on track for diagnosing high-grade urothelial carcinoma with a minimum quantity of five malignant cells in lower tract specimens? Critical analysis of The Paris System Quantitation Criteria. Cancer Cytopathol. 2023;131(11):708-715.

Marx CE, Schenker C, Xu Y, Salvatore SP, Kahn SR, Garcia D, et al. Accuracy and interrater agreement of death event adjudications by physician trainees: validation of the ISTH definition of pulmonary embolism-related death in an autopsy cohort. J Thromb Haemost. 2023;21(10):2908-2912.

Elhadad S, Redmond D, Tan A, Huang J, Rodriguez BL, Racine-Brzostek SE, et al. Defibrotide mitigates endothelial cell injury induced by plasmas from patients with COVID-19 and related vasculopathies. Thromb Res. 2023;225:47-56.

DeSimone RA, Hess AS, Rajendran P, Tanaka KA, Cushing MM, Eichbaum Q. Blood utilization in liver transplantation (BUILT): A multidisciplinary survey of transfusion practices. Transfusion. 2023;63(1):83-91.

Nuzzo PV, Pederzoli F, Saieva C, Zanardi E, Fotia G, Malgeri A, et al. Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer. J Transl Med. 2023;21(1):75.